High-mobility group box-1 in sterile inflammation

Journal of Internal Medicine

Volumn 276, Issue 5, 2014, Pages 425-443

  Tsung, A ^a   Tohme, S ^a   Billiar, T R ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Damage associated molecular pattern; HMGB1; Immune system; Inflammation

Indexed keywords

ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; CHEMOKINE RECEPTOR CXCR4; CXCR4 PROTEIN, HUMAN; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN RECEPTOR; STROMAL CELL DERIVED FACTOR 1; TOLL LIKE RECEPTOR;

ANIMAL; CELL COMPARTMENTALIZATION; HUMAN; IMMUNOLOGY; INFLAMMATION; INNATE IMMUNITY; METABOLISM; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CELL COMPARTMENTATION; CHEMOKINE CXCL12; HMGB1 PROTEIN; HUMANS; IMMUNITY, INNATE; INFLAMMATION; OXIDATION-REDUCTION; RECEPTORS, CXCR4; RECEPTORS, IMMUNOLOGIC; TOLL-LIKE RECEPTORS;

EID: 84908640980     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12276     Document Type: Review

References (191)

1. Medawar PB, Woodruff MF. The induction of tolerance by skin homografts on newborn rats. Immunology 1958; 1: 27-35.
2. Medawar PB. Immunological tolerance. Science 1961; 133: 303-6.
3. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991-1045.
4. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296: 301-5.
5. Medzhitov R, Janeway CA Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell 1997; 91: 295-8.
6. Medzhitov R, Janeway CA Jr. Decoding the patterns of self and nonself by the innate immune system. Science 2002; 296: 298-300.
7. Haraldsen G, Balogh J, Pollheimer J, Sponheim J, Kuchler AM. Interleukin-33 - cytokine of dual function or novel alarmin? Trends Immunol 2009; 30: 227-33.
8. Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci USA 2009; 106: 9021-6.
9. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009; 27: 229-65.
10. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440: 237-41.
11. Halle A, Hornung V, Petzold GC et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 2008; 9: 857-65.
12. Foell D, Wittkowski H, Vogl T, Roth J. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007; 81: 28-37.
13. Taylor KR, Trowbridge JM, Rudisill JA, Termeer CC, Simon JC, Gallo RL. Hyaluronan fragments stimulate endothelial recognition of injury through TLR4. J Biol Chem 2004; 279: 17079-84.
14. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21: 335-76.
15. Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 2011; 29: 139-62.
16. Wang H, Bloom O, Zhang M et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248-51.
17. Abeyama K, Stern DM, Ito Y et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 2005; 115: 1267-74.
18. Qin S, Wang H, Yuan R et al. Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med 2006; 203: 1637-42.
19. Yang H, Ochani M, Li J et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 2004; 101: 296-301.
20. Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A. HMGB1: endogenous danger signaling. Mol Med 2008; 14: 476-84.
21. Venereau E, Casalgrandi M, Schiraldi M et al. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med 2012; 209: 1519-28.
22. Palumbo R, Galvez BG, Pusterla T et al. Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-kappaB activation. J Cell Biol 2007; 179: 33-40.
23. Kazama H, Ricci JE, Herndon JM, Hoppe G, Green DR, Ferguson TA. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 2008; 29: 21-32.
24. Bustin M, Reeves R. High-mobility-group chromosomal proteins: architectural components that facilitate chromatin function. Prog Nucleic Acid Res Mol Biol 1996; 54: 35-100.
25. Bustin M, Lehn DA, Landsman D. Structural features of the HMG chromosomal proteins and their genes. Biochim Biophys Acta 1990; 1049: 231-43.
26. Boonyaratanakornkit V, Melvin V, Prendergast P et al. High-mobility group chromatin proteins 1 and 2 functionally interact with steroid hormone receptors to enhance their DNA binding in vitro and transcriptional activity in mammalian cells. Mol Cell Biol 1998; 18: 4471-87.
27. Melvin VS, Edwards DP. Coregulatory proteins in steroid hormone receptor action: the role of chromatin high mobility group proteins HMG-1 and -2. Steroids 1999; 64: 576-86.
28. Celona B, Weiner A, Di Felice F et al. Substantial histone reduction modulates genomewide nucleosomal occupancy and global transcriptional output. PLoS Biol 2011; 9: e1001086.
29. Schroter H, Bode J. The binding sites for large and small high-mobility-group (HMG) proteins. Studies on HMG-nucleosome interactions in vitro. Eur J Biochem 1982; 127: 429-36.
30. Nightingale K, Dimitrov S, Reeves R, Wolffe AP. Evidence for a shared structural role for HMG1 and linker histones B4 and H1 in organizing chromatin. EMBO J 1996; 15: 548-61.
31. Das D, Scovell WM. The binding interaction of HMG-1 with the TATA-binding protein/TATA complex. J Biol Chem 2001; 276: 32597-605.
32. Jayaraman L, Moorthy NC, Murthy KG, Manley JL, Bustin M, Prives C. High mobility group protein-1 (HMG-1) is a unique activator of p53. Genes Dev 1998; 12: 462-72.
33. Jiao Y, Wang HC, Fan SJ. Growth suppression and radiosensitivity increase by HMGB1 in breast cancer. Acta Pharmacol Sin 2007; 28: 1957-67.
34. Melvin VS, Harrell C, Adelman JS, Kraus WL, Churchill M, Edwards DP. The role of the C-terminal extension (CTE) of the estrogen receptor alpha and beta DNA binding domain in DNA binding and interaction with HMGB. J Biol Chem 2004; 279: 14763-71.
35. Huang H, Nace GW, McDonald KA et al. Hepatocyte specific HMGB1 deletion worsens the injury in liver ischemia/reperfusion: a role for intracellular HMGB1 in cellular protection. Hepatology 2014; 59: 1984-97.
36. Kang R, Zhang Q, Hou W et al. Intracellular HMGB1 inhibits inflammatory nucleosome release and limits acute pancreatitis in mice. Gastroenterology 2014; 146: 1097-107.
37. Yanai H, Matsuda A, An J et al. Conditional ablation of HMGB1 in mice reveals its protective function against endotoxemia and bacterial infection. Proc Natl Acad Sci USA 2013; 110: 20699-704.
38. Calogero S, Grassi F, Aguzzi A et al. The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat Genet 1999; 22: 276-80.
39. Lange SS, Reddy MC, Vasquez KM. Human HMGB1 directly facilitates interactions between nucleotide excision repair proteins on triplex-directed psoralen interstrand crosslinks. DNA Repair (Amst) 2009; 8: 865-72.
40. Yuan F, Gu L, Guo S, Wang C, Li GM. Evidence for involvement of HMGB1 protein in human DNA mismatch repair. J Biol Chem 2004; 279: 20935-40.
41. Zhang Y, Yuan F, Presnell SR et al. Reconstitution of 5'-directed human mismatch repair in a purified system. Cell 2005; 122: 693-705.
42. Prasad R, Liu Y, Deterding LJ et al. HMGB1 is a cofactor in mammalian base excision repair. Mol Cell 2007; 27: 829-41.
43. Lange SS, Vasquez KM. HMGB1: the jack-of-all-trades protein is a master DNA repair mechanic. Mol Carcinog 2009; 48: 571-80.
44. Bianchi ME, Agresti A. HMG proteins: dynamic players in gene regulation and differentiation. Curr Opin Genet Dev 2005; 15: 496-506.
45. Willingham SB, Allen IC, Bergstralh DT et al. NLRP3 (NALP3, Cryopyrin) facilitates in vivo caspase-1 activation, necrosis, and HMGB1 release via inflammasome-dependent and -independent pathways. J Immunol 2009; 183: 2008-15.
46. Gerlitz G, Hock R, Ueda T, Bustin M. The dynamics of HMG protein-chromatin interactions in living cells. Biochem Cell Biol 2009; 87: 127-37.
47. Lu B, Nakamura T, Inouye K et al. Novel role of PKR in inflammasome activation and HMGB1 release. Nature 2012; 488: 670-4.
48. Tang D, Kang R, Livesey KM, Zeh HJ III, Lotze MT. High mobility group box 1 (HMGB1) activates an autophagic response to oxidative stress. Antioxid Redox Signal 2011; 15: 2185-95.
49. Tang D, Kang R, Cheh CW et al. HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene 2010; 29: 5299-310.
50. Tang D, Kang R, Livesey KM et al. Endogenous HMGB1 regulates autophagy. J Cell Biol 2010; 190: 881-92.
51. Kang R, Zeh HJ, Lotze MT, Tang D. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ 2011; 18: 571-80.
52. Tang D, Kang R, Livesey KM et al. High-mobility group box 1 is essential for mitochondrial quality control. Cell Metab 2011; 13: 701-11.
53. Widlak P, Garrard WT. Discovery, regulation, and action of the major apoptotic nucleases DFF40/CAD and endonuclease G. J Cell Biochem 2005; 94: 1078-87.
54. Tamura T, Yanai H, Savitsky D, Taniguchi T. The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol 2008; 26: 535-84.
55. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010; 11: 373-84.
56. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007; 449: 819-26.
57. Krieg AM, Yi AK, Matson S et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374: 546-9.
58. Ishii KJ, Coban C, Kato H et al. A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat Immunol 2006; 7: 40-8.
59. Takaoka A, Wang Z, Choi MK et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 2007; 448: 501-5.
60. Yanai H, Ban T, Wang Z et al. HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature 2009; 462: 99-103.
61. Chiba S, Baghdadi M, Akiba H et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol 2012; 13: 832-42.
62. Harris HE, Andersson U, Pisetsky DS. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol 2012; 8: 195-202.
63. Yang H, Wang H, Czura CJ, Tracey KJ. The cytokine activity of HMGB1. J Leukoc Biol 2005; 78: 1-8.
64. Izuishi K, Tsung A, Jeyabalan G et al. Cutting edge: high-mobility group box 1 preconditioning protects against liver ischemia-reperfusion injury. J Immunol 2006; 176: 7154-8.
65. Tsung A, Klune JR, Zhang X et al. HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J Exp Med 2007; 204: 2913-23.
66. Tsung A, Sahai R, Tanaka H et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 2005; 201: 1135-43.
67. Bell CW, Jiang W, Reich CF III, Pisetsky DS. The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol 2006; 291: C1318-25.
68. Kim S, Kim SY, Pribis JP et al. Signaling of high mobility group box 1 (HMGB1) through toll-like receptor 4 in macrophages requires CD14. Mol Med 2013; 19: 88-98.
69. Xu D, Young J, Song D, Esko JD. Heparan sulfate is essential for high mobility group protein 1 (HMGB1) signaling by the receptor for advanced glycation end products (RAGE). J Biol Chem 2011; 286: 41736-44.
70. Tian J, Avalos AM, Mao SY et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007; 8: 487-96.
71. Chen GY, Tang J, Zheng P, Liu Y. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 2009; 323: 1722-5.
72. Van de Wouwer M, Collen D, Conway EM. Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol 2004; 24: 1374-83.
73. Ito T, Kawahara K, Nakamura T et al. High-mobility group box 1 protein promotes development of microvascular thrombosis in rats. J Thromb Haemost 2007; 5: 109-16.
74. Hoppe G, Talcott KE, Bhattacharya SK, Crabb JW, Sears JE. Molecular basis for the redox control of nuclear transport of the structural chromatin protein Hmgb1. Exp Cell Res 2006; 312: 3526-38.
75. Yang H, Lundback P, Ottosson L et al. Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol Med 2012; 18: 250-9.
76. Schiraldi M, Raucci A, Munoz LM et al. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med 2012; 209: 551-63.
77. Yang H, Hreggvidsdottir HS, Palmblad K et al. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci USA 2010; 107: 11942-7.
78. Antoine DJ, Jenkins RE, Dear JW et al. Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. J Hepatol 2012; 56: 1070-9.
79. Antoine DJ, Williams DP, Kipar A, Laverty H, Park BK. Diet restriction inhibits apoptosis and HMGB1 oxidation and promotes inflammatory cell recruitment during acetaminophen hepatotoxicity. Mol Med 2010; 16: 479-90.
80. Mollen KP, Anand RJ, Tsung A, Prince JM, Levy RM, Billiar TR. Emerging paradigm: toll-like receptor 4-sentinel for the detection of tissue damage. Shock 2006; 26: 430-7.
81. Park JS, Svetkauskaite D, He Q et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004; 279: 7370-7.
82. Park JS, Gamboni-Robertson F, He Q et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006; 290: C917-24.
83. Fan J, Li Y, Levy RM et al. Hemorrhagic shock induces NAD(P)H oxidase activation in neutrophils: role of HMGB1-TLR4 signaling. J Immunol 2007; 178: 6573-80.
84. Yu M, Wang H, Ding A et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 2006; 26: 174-9.
85. Hori O, Brett J, Slattery T et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 1995; 270: 25752-61.
86. Ramasamy R, Yan SF, Schmidt AM. RAGE: therapeutic target and biomarker of the inflammatory response-the evidence mounts. J Leukoc Biol 2009; 86: 505-12.
87. Huttunen HJ, Fages C, Kuja-Panula J, Ridley AJ, Rauvala H. Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res 2002; 62: 4805-11.
88. Penzo M, Molteni R, Suda T et al. Inhibitor of NF-kappa B kinases alpha and beta are both essential for high mobility group box 1-mediated chemotaxis [corrected]. J Immunol 2010; 184: 4497-509.
89. Andersson U, Wang H, Palmblad K et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000; 192: 565-70.
90. Taguchi A, Blood DC, del Toro G et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000; 405: 354-60.
91. Degryse B, Bonaldi T, Scaffidi P et al. The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol 2001; 152: 1197-206.
92. Orlova VV, Choi EY, Xie C et al. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J 2007; 26: 1129-39.
93. Chavakis E, Hain A, Vinci M et al. High-mobility group box 1 activates integrin-dependent homing of endothelial progenitor cells. Circ Res 2007; 100: 204-12.
94. Fiuza C, Bustin M, Talwar S et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003; 101: 2652-60.
95. Xiang M, Yuan Y, Fan L et al. Role of macrophages in mobilization of hematopoietic progenitor cells from bone marrow after hemorrhagic shock. Shock 2012; 37: 518-23.
96. Rauvala H, Pihlaskari R. Isolation and some characteristics of an adhesive factor of brain that enhances neurite outgrowth in central neurons. J Biol Chem 1987; 262: 16625-35.
97. Rauvala H, Rouhiainen A. RAGE as a receptor of HMGB1 (Amphoterin): roles in health and disease. Curr Mol Med 2007; 7: 725-34.
98. Kew RR, Penzo M, Habiel DM, Marcu KB. The IKKalpha-dependent NF-kappaB p52/RelB noncanonical pathway is essential to sustain a CXCL12 autocrine loop in cells migrating in response to HMGB1. J Immunol 2012; 188: 2380-6.
99. Campana L, Bosurgi L, Bianchi ME, Manfredi AA, Rovere-Querini P. Requirement of HMGB1 for stromal cell-derived factor-1/CXCL12-dependent migration of macrophages and dendritic cells. J Leukoc Biol 2009; 86: 609-15.
100. Dumitriu IE, Bianchi ME, Bacci M, Manfredi AA, Rovere-Querini P. The secretion of HMGB1 is required for the migration of maturing dendritic cells. J Leukoc Biol 2007; 81: 84-91.
101. Gardella S, Andrei C, Ferrera D et al. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep 2002; 3: 995-1001.
102. Youn JH, Shin JS. Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion. J Immunol 2006; 177: 7889-97.
103. Bonaldi T, Talamo F, Scaffidi P et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 2003; 22: 5551-60.
104. Ito I, Fukazawa J, Yoshida M. Post-translational methylation of high mobility group box 1 (HMGB1) causes its cytoplasmic localization in neutrophils. J Biol Chem 2007; 282: 16336-44.
105. Evankovich J, Cho SW, Zhang R et al. High mobility group box 1 release from hepatocytes during ischemia and reperfusion injury is mediated by decreased histone deacetylase activity. J Biol Chem 2010; 285: 39888-97.
106. Oh YJ, Youn JH, Ji Y et al. HMGB1 is phosphorylated by classical protein kinase C and is secreted by a calcium-dependent mechanism. J Immunol 2009; 182: 5800-9.
107. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418: 191-5.
108. Bustin M. Revised nomenclature for high mobility group (HMG) chromosomal proteins. Trends Biochem Sci 2001; 26: 152-3.
109. Kokkola R, Sundberg E, Ulfgren AK et al. High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis. Arthritis Rheum 2002; 46: 2598-603.
110. Muller S, Scaffidi P, Degryse B et al. New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J 2001; 20: 4337-40.
111. Apetoh L, Tesniere A, Ghiringhelli F, Kroemer G, Zitvogel L. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res 2008; 68: 4026-30.
112. Apetoh L, Ghiringhelli F, Tesniere A et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 2007; 220: 47-59.
113. Lamkanfi M, Sarkar A, Vande Walle L et al. Inflammasome-dependent release of the alarmin HMGB1 in endotoxemia. J Immunol 2010; 185: 4385-92.
114. Tsung A, Stang MT, Ikeda A et al. The transcription factor interferon regulatory factor-1 mediates liver damage during ischemia-reperfusion injury. Am J Physiol Gastrointest Liver Physiol 2006; 290: G1261-8.
115. Ilmakunnas M, Tukiainen EM, Rouhiainen A et al. High mobility group box 1 protein as a marker of hepatocellular injury in human liver transplantation. Liver Transpl 2008; 14: 1517-25.
116. Kim JB, Sig Choi J, Yu YM et al. HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. J Neurosci 2006; 26: 6413-21.
117. Kim JB, Lim CM, Yu YM, Lee JK. Induction and subcellular localization of high-mobility group box-1 (HMGB1) in the postischemic rat brain. J Neurosci Res 2008; 86: 1125-31.
118. Faraco G, Fossati S, Bianchi ME et al. High mobility group box 1 protein is released by neural cells upon different stresses and worsens ischemic neurodegeneration in vitro and in vivo. J Neurochem 2007; 103: 590-603.
119. Wu H, Chen G, Wyburn KR et al. TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest 2007; 117: 2847-59.
120. Oyama J, Blais C Jr, Liu X et al. Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation 2004; 109: 784-9.
121. Goldstein RS, Gallowitsch-Puerta M, Yang L et al. Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock 2006; 25: 571-4.
122. Andrassy M, Volz HC, Igwe JC et al. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 2008; 117: 3216-26.
123. Oozawa S, Mori S, Kanke T et al. Effects of HMGB1 on ischemia-reperfusion injury in the rat heart. Circ J 2008; 72: 1178-84.
124. Kitahara T, Takeishi Y, Harada M et al. High-mobility group box 1 restores cardiac function after myocardial infarction in transgenic mice. Cardiovasc Res 2008; 80: 40-6.
125. Germani A, Limana F, Capogrossi MC. Pivotal advances: high-mobility group box 1 protein-a cytokine with a role in cardiac repair. J Leukoc Biol 2007; 81: 41-5.
126. Huang Y, Yin H, Han J et al. Extracellular hmgb1 functions as an innate immune-mediator implicated in murine cardiac allograft acute rejection. Am J Transplant 2007; 7: 799-808.
127. Sachdev U, Cui X, Tzeng E. HMGB1 and TLR4 mediate skeletal muscle recovery in a murine model of hindlimb ischemia. J Vasc Surg 2013; 58: 460-9.
128. Qiu J, Nishimura M, Wang Y et al. Early release of HMGB-1 from neurons after the onset of brain ischemia. J Cereb Blood Flow Metab 2008; 28: 927-38.
129. Pedrazzi M, Raiteri L, Bonanno G et al. Stimulation of excitatory amino acid release from adult mouse brain glia subcellular particles by high mobility group box 1 protein. J Neurochem 2006; 99: 827-38.
130. Bonanno G, Raiteri L, Milanese M et al. The high-mobility group box 1 cytokine induces transporter-mediated release of glutamate from glial subcellular particles (gliosomes) prepared from in situ-matured astrocytes. Int Rev Neurobiol 2007; 82: 73-93.
131. Agnello D, Wang H, Yang H, Tracey KJ, Ghezzi P. HMGB-1, a DNA-binding protein with cytokine activity, induces brain TNF and IL-6 production, and mediates anorexia and taste aversion. Cytokine 2002; 18: 231-6.
132. Pedrazzi M, Patrone M, Passalacqua M et al. Selective proinflammatory activation of astrocytes by high-mobility group box 1 protein signaling. J Immunol 2007; 179: 8525-32.
133. Liu K, Mori S, Takahashi HK et al. Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats. FASEB J 2007; 21: 3904-16.
134. Maroso M, Balosso S, Ravizza T et al. Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat Med 2010; 16: 413-9.
135. Rabadi MM, Ghaly T, Goligorksy MS, Ratliff BB. HMGB1 in renal ischemic injury. Am J Physiol Renal Physiol 2012; 303: F873-85.
136. Wu H, Steenstra R, de Boer EC et al. Preconditioning with recombinant high-mobility group box 1 protein protects the kidney against ischemia-reperfusion injury in mice. Kidney Int 2014; 85: 824-32.
137. Yang R, Harada T, Mollen KP et al. Anti-HMGB1 neutralizing antibody ameliorates gut barrier dysfunction and improves survival after hemorrhagic shock. Mol Med 2006; 12: 105-14.
138. Kim JY, Park JS, Strassheim D et al. HMGB1 contributes to the development of acute lung injury after hemorrhage. Am J Physiol Lung Cell Mol Physiol 2005; 288: L958-65.
139. Levy RM, Mollen KP, Prince JM et al. Systemic inflammation and remote organ injury following trauma require HMGB1. Am J Physiol Regul Integr Comp Physiol 2007; 293: R1538-44.
140. Levy RM, Prince JM, Yang R et al. Systemic inflammation and remote organ damage following bilateral femur fracture requires Toll-like receptor 4. Am J Physiol Regul Integr Comp Physiol 2006; 291: R970-6.
141. Kocsis AK, Szabolcs A, Hofner P et al. Plasma concentrations of high-mobility group box protein 1, soluble receptor for advanced glycation end-products and circulating DNA in patients with acute pancreatitis. Pancreatology 2009; 9: 383-91.
142. Yasuda T, Ueda T, Shinzeki M et al. Increase of high-mobility group box chromosomal protein 1 in blood and injured organs in experimental severe acute pancreatitis. Pancreas 2007; 34: 487-8.
143. Sawa H, Ueda T, Takeyama Y et al. Blockade of high mobility group box-1 protein attenuates experimental severe acute pancreatitis. World J Gastroenterol 2006; 12: 7666-70.
144. Cheng BQ, Liu CT, Li WJ et al. Ethyl pyruvate improves survival and ameliorates distant organ injury in rats with severe acute pancreatitis. Pancreas 2007; 35: 256-61.
145. Yuan H, Jin X, Sun J et al. Protective effect of HMGB1 a box on organ injury of acute pancreatitis in mice. Pancreas 2009; 38: 143-8.
146. Nadatani Y, Watanabe T, Tanigawa T et al. High mobility group box 1 promotes small intestinal damage induced by nonsteroidal anti-inflammatory drugs through Toll-like receptor 4. Am J Pathol 2012; 181: 98-110.
147. Zamora R, Grishin A, Wong C et al. High-mobility group box 1 protein is an inflammatory mediator in necrotizing enterocolitis: protective effect of the macrophage deactivator semapimod. Am J Physiol Gastrointest Liver Physiol 2005; 289: G643-52.
148. Oktayoglu P, Em S, Tahtasiz M et al. Elevated serum levels of high mobility group box protein 1 (HMGB1) in patients with ankylosing spondylitis and its association with disease activity and quality of life. Rheumatol Int 2013; 33: 1327-31.
149. Ulfgren AK, Grundtman C, Borg K et al. Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids. Arthritis Rheum 2004; 50: 1586-94.
150. Ek M, Popovic K, Harris HE, Naucler CS, Wahren-Herlenius M. Increased extracellular levels of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in minor salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 2006; 54: 2289-94.
151. Abdulahad DA, Westra J, Bijzet J, Limburg PC, Kallenberg CG, Bijl M. High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus. Arthritis Res Ther 2011; 13: R71.
152. Rosenberg AM, Cordeiro DM. Relationship between sex and antibodies to high mobility group proteins 1 and 2 in juvenile idiopathic arthritis. J Rheumatol 2000; 27: 2489-93.
153. Li ZC, Cheng GQ, Hu KZ et al. Correlation of synovial fluid HMGB-1 levels with radiographic severity of knee osteoarthritis. Clin Invest Med 2011; 34: E298.
154. Pullerits R, Jonsson IM, Kollias G, Tarkowski A. Induction of arthritis by high mobility group box chromosomal protein 1 is independent of tumour necrosis factor signalling. Arthritis Res Ther 2008; 10: R72.
155. Kokkola R, Li J, Sundberg E et al. Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum 2003; 48: 2052-8.
156. Hamada T, Torikai M, Kuwazuru A et al. Extracellular high mobility group box chromosomal protein 1 is a coupling factor for hypoxia and inflammation in arthritis. Arthritis Rheum 2008; 58: 2675-85.
157. Liu-Bryan R, Terkeltaub R. Chondrocyte innate immune myeloid differentiation factor 88-dependent signaling drives procatabolic effects of the endogenous Toll-like receptor 2/Toll-like receptor 4 ligands low molecular weight hyaluronan and high mobility group box chromosomal protein 1 in mice. Arthritis Rheum 2010; 62: 2004-12.
158. Pullerits R, Jonsson IM, Verdrengh M et al. High mobility group box chromosomal protein 1, a DNA binding cytokine, induces arthritis. Arthritis Rheum 2003; 48: 1693-700.
159. Ostberg T, Wahamaa H, Palmblad K et al. Oxaliplatin retains HMGB1 intranuclearly and ameliorates collagen type II-induced arthritis. Arthritis Res Ther 2008; 10: R1.
160. van Maanen MA, Lebre MC, van der Poll T et al. Stimulation of nicotinic acetylcholine receptors attenuates collagen-induced arthritis in mice. Arthritis Rheum 2009; 60: 114-22.
161. Hofmann MA, Drury S, Hudson BI et al. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun 2002; 3: 123-35.
162. Van de Wouwer M, Plaisance S, De Vriese A et al. The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis. J Thromb Haemost 2006; 4: 1813-24.
163. Zetterstrom CK, Jiang W, Wahamaa H et al. Pivotal advance: inhibition of HMGB1 nuclear translocation as a mechanism for the anti-rheumatic effects of gold sodium thiomalate. J Leukoc Biol 2008; 83: 31-8.
164. Li J, Xie H, Wen T, Liu H, Zhu W, Chen X. Expression of high mobility group box chromosomal protein 1 and its modulating effects on downstream cytokines in systemic lupus erythematosus. J Rheumatol 2010; 37: 766-75.
165. Urbonaviciute V, Furnrohr BG, Meister S et al. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med 2008; 205: 3007-18.
166. Barkauskaite V, Ek M, Popovic K, Harris HE, Wahren-Herlenius M, Nyberg F. Translocation of the novel cytokine HMGB1 to the cytoplasm and extracellular space coincides with the peak of clinical activity in experimentally UV-induced lesions of cutaneous lupus erythematosus. Lupus 2007; 16: 794-802.
167. Jiang W, Pisetsky DS. Expression of high mobility group protein 1 in the sera of patients and mice with systemic lupus erythematosus. Ann Rheum Dis 2008; 67: 727-8.
168. Grundtman C, Bruton J, Yamada T et al. Effects of HMGB1 on in vitro responses of isolated muscle fibers and functional aspects in skeletal muscles of idiopathic inflammatory myopathies. FASEB J 2010; 24: 570-8.
169. Yoshizaki A, Komura K, Iwata Y et al. Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity. J Clin Immunol 2009; 29: 180-9.
170. Hamada N, Maeyama T, Kawaguchi T et al. The role of high mobility group box1 in pulmonary fibrosis. Am J Respir Cell Mol Biol 2008; 39: 440-7.
171. Mittal D, Saccheri F, Venereau E, Pusterla T, Bianchi ME, Rescigno M. TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. EMBO J 2010; 29: 2242-52.
172. Han J, Zhong J, Wei W et al. Extracellular high-mobility group box 1 acts as an innate immune mediator to enhance autoimmune progression and diabetes onset in NOD mice. Diabetes 2008; 57: 2118-27.
173. Matsuoka N, Itoh T, Watarai H et al. High-mobility group box 1 is involved in the initial events of early loss of transplanted islets in mice. J Clin Invest 2010; 120: 735-43.
174. Li T, Zuo X, Zhou Y et al. The vagus nerve and nicotinic receptors involve inhibition of HMGB1 release and early pro-inflammatory cytokines function in collagen-induced arthritis. J Clin Immunol 2010; 30: 213-20.
175. Yang R, Shaufl AL, Killeen ME, Fink MP. Ethyl pyruvate ameliorates liver injury secondary to severe acute pancreatitis. J Surg Res 2009; 153: 302-9.
176. Ulloa L, Ochani M, Yang H et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci USA 2002; 99: 12351-6.
177. Dave SH, Tilstra JS, Matsuoka K et al. Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. J Leukoc Biol 2009; 86: 633-43.
178. Cardinal J, Pan P, Dhupar R et al. Cisplatin prevents high mobility group box 1 release and is protective in a murine model of hepatic ischemia/reperfusion injury. Hepatology 2009; 50: 565-74.
179. Wang X, Sun R, Wei H, Tian Z. High-mobility group box 1 (HMGB1)-Toll-like receptor (TLR)4-interleukin (IL)-23-IL-17A axis in drug-induced damage-associated lethal hepatitis: interaction of gammadelta T cells with macrophages. Hepatology 2013; 57: 373-84.
180. Wang W, Zhao F, Fang Y et al. Glycyrrhizin protects against porcine endotoxemia through modulation of systemic inflammatory response. Crit Care 2013; 17: R44.
181. Ogiku M, Kono H, Hara M, Tsuchiya M, Fujii H. Glycyrrhizin prevents liver injury by inhibition of high-mobility group box 1 production by Kupffer cells after ischemia-reperfusion in rats. J Pharmacol Exp Ther 2011; 339: 93-8.
182. Mollica L, De Marchis F, Spitaleri A et al. Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem Biol 2007; 14: 431-41.
183. Ledford JG, Lo B, Kislan MM et al. Surfactant protein-A inhibits mycoplasma-induced dendritic cell maturation through regulation of HMGB-1 cytokine activity. J Immunol 2010; 185: 3884-94.
184. Gong G, Yuan LB, Hu L et al. Glycyrrhizin attenuates rat ischemic spinal cord injury by suppressing inflammatory cytokines and HMGB1. Acta Pharmacol Sin 2012; 33: 11-8.
185. Zhu H, Li J, Wang S, Liu K, Wang L, Huang L. Hmgb1-TLR4-IL-23-IL-17A axis promote ischemia-reperfusion injury in a cardiac transplantation model. Transplantation 2013; 95: 1448-54.
186. Kim SW, Jin Y, Shin JH et al. Glycyrrhizic acid affords robust neuroprotection in the postischemic brain via anti-inflammatory effect by inhibiting HMGB1 phosphorylation and secretion. Neurobiol Dis 2012; 46: 147-56.
187. Sun Q, Wang F, Li W et al. Glycyrrhizic acid confers neuroprotection after subarachnoid hemorrhage via inhibition of high mobility group box-1 protein: a hypothesis for novel therapy of subarachnoid hemorrhage. Med Hypotheses 2013; 81: 681-5.
188. Chen J, Zhang J, Xu L et al. Inhibition of neointimal hyperplasia in the rat carotid artery injury model by a HMGB1 inhibitor. Atherosclerosis 2012; 224: 332-9.
189. Muhammad S, Barakat W, Stoyanov S et al. The HMGB1 receptor RAGE mediates ischemic brain damage. J Neurosci 2008; 28: 12023-31.
190. Raman KG, Sappington PL, Yang R et al. The role of RAGE in the pathogenesis of intestinal barrier dysfunction after hemorrhagic shock. Am J Physiol Gastrointest Liver Physiol 2006; 291: G556-65.
191. Gero D, Szoleczky P, Modis K et al. Identification of pharmacological modulators of HMGB1-induced inflammatory response by cell-based screening. PLoS ONE 2013; 8: e65994.